Needham & Company LLC Reiterates Hold Rating for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD)‘s stock had its “hold” rating restated by stock analysts at Needham & Company LLC in a report issued on Wednesday,Benzinga reports.

GILD has been the topic of several other research reports. Wells Fargo & Company upped their price objective on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Morgan Stanley increased their price objective on Gilead Sciences from $113.00 to $123.00 and gave the company an “overweight” rating in a research note on Wednesday. Mizuho raised their target price on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Piper Sandler raised their price objective on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Finally, BMO Capital Markets raised their price objective on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, fourteen have issued a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $101.33.

Gilead Sciences Stock Up 2.6 %

NASDAQ GILD opened at $105.96 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The company has a fifty day moving average of $93.38 and a two-hundred day moving average of $87.24. The firm has a market capitalization of $132.05 billion, a price-to-earnings ratio of 1,177.33, a PEG ratio of 1.25 and a beta of 0.18. Gilead Sciences has a 52 week low of $62.07 and a 52 week high of $106.43.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. On average, analysts predict that Gilead Sciences will post 4.35 earnings per share for the current year.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 137,676 shares of the business’s stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the sale, the chief financial officer now directly owns 171,223 shares in the company, valued at approximately $17,502,415.06. The trade was a 44.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares in the company, valued at $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 710,500 shares of company stock worth $67,684,956. 0.16% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors have recently added to or reduced their stakes in the business. nVerses Capital LLC acquired a new position in Gilead Sciences in the third quarter valued at $25,000. HHM Wealth Advisors LLC increased its stake in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the last quarter. Valued Wealth Advisors LLC increased its stake in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares during the last quarter. YANKCOM Partnership acquired a new position in Gilead Sciences in the fourth quarter valued at $28,000. Finally, Decker Retirement Planning Inc. acquired a new position in Gilead Sciences in the fourth quarter valued at $29,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.